Esperion Therapeutics Inc (ESPR)
2.065
+0.02
(+1.23%)
USD |
NASDAQ |
May 02, 16:00
2.065
0.00 (0.00%)
After-Hours: 17:59
Esperion Therapeutics Cash from Financing (Quarterly): 4.471M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.471M |
| September 30, 2023 | -4.312M |
| June 30, 2023 | 0.809M |
| March 31, 2023 | 49.49M |
| December 31, 2022 | -30.36M |
| September 30, 2022 | 46.29M |
| June 30, 2022 | 18.11M |
| March 31, 2022 | -1.436M |
| December 31, 2021 | 213.41M |
| September 30, 2021 | 3.655M |
| June 30, 2021 | 49.11M |
| March 31, 2021 | 2.045M |
| December 31, 2020 | 170.44M |
| September 30, 2020 | 1.597M |
| June 30, 2020 | 3.674M |
| March 31, 2020 | 26.01M |
| December 31, 2019 | 7.014M |
| September 30, 2019 | 0.976M |
| June 30, 2019 | 126.54M |
| March 31, 2019 | 1.669M |
| December 31, 2018 | 0.342M |
| September 30, 2018 | -0.126M |
| June 30, 2018 | 1.185M |
| March 31, 2018 | 9.293M |
| Date | Value |
|---|---|
| December 31, 2017 | -0.081M |
| September 30, 2017 | 164.06M |
| June 30, 2017 | -0.369M |
| March 31, 2017 | -0.15M |
| December 31, 2016 | -0.411M |
| September 30, 2016 | -0.394M |
| June 30, 2016 | -0.39M |
| March 31, 2016 | -0.364M |
| December 31, 2015 | -0.384M |
| September 30, 2015 | 0.126M |
| June 30, 2015 | 0.366M |
| March 31, 2015 | 190.41M |
| December 31, 2014 | 91.90M |
| September 30, 2014 | 0.134M |
| June 30, 2014 | 5.037M |
| March 31, 2014 | 0.052M |
| December 31, 2013 | -0.174M |
| September 30, 2013 | 73.43M |
| June 30, 2013 | 15.88M |
| March 31, 2013 | 0.00 |
| December 31, 2012 | 5.715M |
| September 30, 2012 | 4.019M |
| June 30, 2012 | 0.0174M |
| March 31, 2012 | 6.00M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-30.36M
Minimum
Dec 2022
213.41M
Maximum
Dec 2021
36.19M
Average
4.471M
Median
Dec 2023
Cash from Financing (Quarterly) Benchmarks
| United Therapeutics Corp | -92.80M |
| Dynavax Technologies Corp | 1.776M |
| Heron Therapeutics Inc | 0.199M |
| Aldeyra Therapeutics Inc | -1.012M |
| Deciphera Pharmaceuticals Inc | 0.89M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -37.06M |
| Free Cash Flow | -135.49M |
| Free Cash Flow Per Share (Quarterly) | -0.3294 |
| Free Cash Flow to Equity (Quarterly) | -37.49M |
| Free Cash Flow Yield | -63.69% |